Pharmaceuticals, Biotechnology and Life Sciences
SBTI ID
40007383
Localisation
Belgium
Europe
Secteur d'activité
Pharmaceuticals, Biotechnology and Life Sciences
Type d'organisation
Corporate
Dernière mise à jour
21/11/2024
Statut
Classification
1.5°C
Année cible
2030
Statut
Targets set
Classification
1.5°C
Année cible
2045
Overall Net-Zero Target: UCB commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: UCB commits to reduce absolute scope 1 and 2 GHG emissions 73% by 2030 from a 2019 base year.* UCB also commits to reduce absolute scope 3 GHG emissions from fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets and end-of-life treatment of sold products 48% within the same timeframe.* UCB further commits that 80% of its suppliers by emissions covering purchased goods and services, will have science-based targets by 2028. *The target boundary includes land-related emissions and removals from bioenergy feedstocks. Long-Term Targets: UCB commits to reduce absolute scope 1 and 2 GHG emissions 90% by 2045 from a 2019 base year.* UCB commits to reduce absolute scope 3 GHG emissions from purchased goods and services, fuel- and energy-related activities, upstream transportation and distribution, waste generated in operations, business travel, employee commuting, upstream leased assets and end-of-life treatment of sold products 90% within the same timeframe.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks.
Statut
Targets setAnnée cible
2045
The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C
ISIN
BE0003739530
LEI
2138008J191VLSGY5A09
Source : Science Based Targets initiative | Données publiques